Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Samalizumab (ALXN 6000), a humanized monoclonal antibody, selectively targets and inhibits the interaction between CD200 and its receptor (CD200R). This compound is utilized in the research of multiple myeloma and B-cell chronic lymphocytic leukemia [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Samalizumab (ALXN 6000), a humanized monoclonal antibody, selectively targets and inhibits the interaction between CD200 and its receptor (CD200R). This compound is utilized in the research of multiple myeloma and B-cell chronic lymphocytic leukemia [1]. |
In vitro | Samalizumab has been rationally designed featuring an IgG2/G4 constant region to minimize effector functions and preserve immune cell subpopulations. It is a recombinant humanized anti-CD200 monoclonal antibody intended to abrogate effector functions. Samalizumab specifically binds to the immune checkpoint CD200, blocking receptor engagement and signaling, and antagonizes CD200-driven immune suppression, thus mediating an anti-tumor immune response [1]. |
Synonyms | ALXN 6000 |
Molecular Weight | N/A |
CAS No. | 1073059-33-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Samalizumab 1073059-33-2 ALXN 6000 ALXN-6000 ALXN6000 inhibitor inhibit